Maguire Jason D, Sumawinata Iwa W, Masbar Sofyan, Laksana Budhi, Prodjodipuro Purnomo, Susanti Ika, Sismadi Priyanto, Mahmud Nurlis, Bangs Michael J, Baird J Kevin
United States Naval Medical Research Unit #2, Jakarta, Indonesia.
Lancet. 2002 Jul 6;360(9326):58-60. doi: 10.1016/S0140-6736(02)09336-4.
Oral chloroquine is the treatment of choice for uncomplicated Plasmodium malariae infections worldwide. We did a prospective 28-day in-vivo assessment of the efficacy of chloroquine for treatment of P malariae on Legundi Island in Lampung Bay, Sumatra, Indonesia. Of 28 patients, one had recurrent parasitaemia on day 28, and two had persistent parasitaemia to day 8. Whole-blood chloroquine and desethylchloroquine concentrations were at ordinarily effective levels (> or = 100 microg/L) on day 8 in both cases of persistent parasitaemia. These findings suggest that clinical resistance to chloroquine by P malariae occurs in the Indonesian archipelago of southeast Asia.
口服氯喹是全球治疗非复杂性三日疟原虫感染的首选药物。我们在印度尼西亚苏门答腊楠榜湾的勒贡迪岛对氯喹治疗三日疟原虫的疗效进行了为期28天的前瞻性体内评估。28名患者中,1名在第28天出现复发性寄生虫血症,2名至第8天仍有持续性寄生虫血症。在这2例持续性寄生虫血症患者中,第8天时全血氯喹和去乙基氯喹浓度均处于通常有效的水平(≥100微克/升)。这些发现表明,东南亚的印度尼西亚群岛存在三日疟原虫对氯喹的临床耐药性。